



(51) International Patent Classification:

C07D 487/04 (2006.01) *A61P 29/00* (2006.01)
A61K 31/519 (2006.01) *A61P 37/00* (2006.01)

(21) International Application Number:

PCT/US2012/059282

(22) International Filing Date:

9 October 2012 (09.10.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/546,426 12 October 2011 (12.10.2011) US

(71) Applicant: ARRAY BIOPHARMA INC. [US/US]; 3200 Walnut Street, Boulder, Colorado 80301 (US).


(72) Inventors; and

(71) Applicants (for US only): **BOYS, Mark Laurence** [US/US]; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **BURGESS, Laurence E.** [US/US]; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **EARY, C. Todd** [US/US];

c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **GRONEBERG, Robert** [US/US]; 958 Yellow Pine Avenue, Boulder, Colorado 80304 (US). **HACHE, Bruno P.** [CA/US]; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **HARVEY, Darren** [GB/US]; 3 Barker Road, Acton, Massachusetts 01720 (US). **HICKEN, Erik James** [US/US]; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **KRASER, Christopher F.** [US/US]; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **LAIRD, Ellen** [US/US]; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **MORENO, David A.** [US/US]; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **MUNSON, Mark C.** [US/US]; 45 Central Street, Acton, Massachusetts 01720 (US). **REN, Li** [CA/US]; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **ROBINSON, John E.** [US/US]; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **SCHLACHTER, Stephen T.** [US/US]; 2017 Lauraette Drive, Dallas, Texas 75208-3110 (US).

[Continued on next page]

(54) Title: 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES



(57) Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R¹, R², R³, R⁴, R⁵, R⁶, X¹ and X² have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.



(74) **Agents:** HARRIS, Robert J. et al.; Viksnins Harris & Padys PLLP, P.O. Box 111098, St. Paul, Minnesota 55111-1098 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))